HC Wainwright & Co. Maintains Buy Rating for CASI Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has reaffirmed its Buy rating on CASI Pharmaceuticals (NASDAQ:CASI), increasing the price target from $10.00 to $12.00. CASI's stock has risen 1.33% to $4.56 in the last 24 hours. The new price target suggests a potential upside of 163.16%. CASI focuses on commercializing therapeutics for leukemias, lymphomas, and multiple myeloma, with EVOMELA being a key revenue driver.
November 15, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright maintains a Buy rating on CASI Pharmaceuticals with a raised price target from $10 to $12. CASI's stock is up 1.33%, with the new target indicating a 163.16% potential increase.
The reaffirmation of a Buy rating and an increased price target by a reputable analyst firm like HC Wainwright & Co. typically instills confidence in investors and can lead to a positive short-term impact on the stock price. The significant potential upside indicated by the new price target may attract investor interest and buying activity, further supporting the stock's upward movement.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100